WO2026126143 - METHOD OF TREATING CANCER
National phase entry is expected:
Publication Number
WO/2026/126143
Publication Date
18.06.2026
International Application No.
PCT/IB2025/062742
International Filing Date
11.12.2025
Title **
[English]
METHOD OF TREATING CANCER
[French]
MÉTHODE DE TRAITEMENT DU CANCER
Applicants **
NOVARTIS AG
Inventors
CHERFI, Azzeddine
PATHAK, Dhrubajyoti
Priority Data
24220000.4
13.12.2024
EP
25179053.1
27.05.2025
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3545 | |
| EPO | Filing, Examination, Granting | 35793 | |
| Japan | Filing, Examination, Granting | 3447 | |
| South Korea | Filing, Examination, Granting | 4743 | |
| USA | Filing, Examination, Granting | 14540 |
Total:
62,068
Contact Us
Abstract[English]
The present disclosure relates to a method of treating well-differentiated Grade 1 or Grade 2 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a patient in need thereof, comprising administering to said patient a treatment comprising a therapeutically effective dose of a somatostatin receptor (SSTR) targeting radioligand therapeutic (RLT) agent, in particular [177Lu]Lu-DOTA-TATE, as first line therapy.[French]
La présente divulgation concerne une méthode de traitement des tumeurs neuroendocrines gastroentéropancréatiques (TNE-GEP) avancées bien différenciées de grade 1 ou de grade 2 chez un patient qui en a besoin, comprenant l'administration audit patient d'un traitement comprenant une dose thérapeutiquement efficace d'un agent thérapeutique radioligand (RLT) ciblant le récepteur de la somatostatine (SSTR), en particulier le [177Lu]Lu-DOTA-TATE, en tant que thérapie de première ligne.